Vericel VCEL
NASDAQ VCEL
$40.19 -0.28 (-0.69%)
As of: Sep 4, 2026 · 3:59 PM EDT

Vericel (VCEL) Other Accumulated Expenses (2013 - 2026)

Vericel (VCEL) posted Other Accumulated Expenses of $116000.0 for Q2 2026, little changed sequentially from $116000.0 in Q1 2026, and down 1.69% YoY from $118000.0 in Q2 2025.

Analysis

Vericel (VCEL) Other Accumulated Expenses (2013 - 2026) Analysis & Trends

Vericel has reported Other Accumulated Expenses for 14 years, with the latest figure at $116000.0 in Q2 2026.

  • Quarterly Other Accumulated Expenses fell 1.69% year-over-year to $116000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $116000.0 (down 1.69% YoY) and the FY2025 annual result came in at $116000.0, changed 0.0% from the prior year.
  • Other Accumulated Expenses steadied at $116000.0 in Q2 2026 per VCEL's latest filing, from $116000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $118000.0 in Q2 2025 and troughed at $20000.0 in Q1 2023.
  • A 5-year average of $78384.6 and a median of $116000.0 in 2024 frame the typical range for Other Accumulated Expenses.
  • The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses changed 0.0% in 2022, then plunged 51.22% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $41000.0 in 2022, then tumbled by 48.78% to $21000.0 in 2023, then soared by 452.38% to $116000.0 in 2024, then changed by 0.0% to $116000.0 in 2025, then changed by 0.0% to $116000.0 in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods registered $116000.0, $116000.0, and $116000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Vericel 2.05 Bn 1.89 Bn 56.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 116,000.00
Mar 31, 2026 116,000.00
Dec 31, 2025 116,000.00
Sep 30, 2025 116,000.00
Jun 30, 2025 118,000.00
Mar 31, 2025 116,000.00
Dec 31, 2024 116,000.00
Jun 30, 2023 21,000.00
Mar 31, 2023 20,000.00
Dec 31, 2022 41,000.00
Sep 30, 2022 41,000.00
Jun 30, 2022 41,000.00
Mar 31, 2022 41,000.00
Dec 31, 2021 41,000.00
Sep 30, 2021 41,000.00
Jun 30, 2021 41,000.00
Mar 31, 2021 41,000.00
Dec 31, 2020 41,000.00
Sep 30, 2020 41,000.00
Jun 30, 2020 41,000.00